BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company historical holders
total: 20
Torray Fund Bristol-Myers Squibb Company transactions over time
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 2
- Held since:
- 2020 Q1
- Held for:
- 13 quarters
- Latest activity:
- 2023 Q2
Torray Fund has been an institutional investor in Bristol-Myers Squibb Company (BMY) since 2020 Q1. According to 2026 Q1 report, Torray Fund doesn't hold any shares. The fund/company first acquired BMY in 2020 Q1, initially purchasing 163,400 shares. Since the initial investment, Torray Fund has made 4 more transactions in this position.
When did Torray Fund exit their BMY position?
Torray Fund no longer holds Bristol-Myers Squibb Company (BMY). They sold off their entire position in 2023 Q2, closing out an investment that began in 2020 Q1.
When did Torray Fund first invest in BMY?
Torray Fund first invested in Bristol-Myers Squibb Company (BMY) in 2020 Q1 at the reported quarter-end price of $55.74 per share, acquiring 163,400 shares in their initial purchase.
What is Torray Fund's average cost basis for BMY?
Based on historical transaction data, Torray Fund's estimated cost basis for Bristol-Myers Squibb Company (BMY) is approximately $57.46 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $57.46
- Weighted AVG sell price:
- $70.58
BMY transactions history by Torray Fund
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$69.31
|
|
-100% (-157,493)
|
-3.53%
|
|
2022 Q3
|
3.93%
|
157,493
|
$71.09
|
$11,196,177
|
-14.33% (-26,346)
|
-0.62%
|
|
2022 Q2
|
4.67%
|
183,839
|
$77.00
|
$14,155,603
|
-13.72% (-29,231)
|
-0.63%
|
|
2021 Q1
|
3.47%
|
213,070
|
$63.13
|
$13,451,109
|
+30.40% (+49,670)
|
+0.81%
|
|
2020 Q1
|
3.08%
|
$55.74
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.